Johnson & Johnson Acquiring Sinusitis Catheter Technology Company - Acclarent

The venture capital arm of Johnson and Johnson began investing in this company a year ago. This is the second acquisition this week for J and J.

Johnson and Johnson Company, DePuy Orthopedics Acquires Finsbury Orthopaedics from the UK

What is also interesting to note is the direction of J and J as a couple months ago they discontinued funding with a company called Palomar which is a consumer product aimed at reducing wrinkles, so it appears treatments and device are in the fore front over those that would be termed cosmetic products, in other words J and J with this acquisition is getting “nosey” (grin). BD

Johnson and Johnson Cancels Contract with Palomar – Unfavorable Economic Conditions Stated For A Massive Product Launch

From the Acclarent website:

“The Balloon Sinuplasty™ System
Using endoscopic techniques, the Balloon Sinuplasty™ system enables qualified otolaryngologists to dilate obstructed sinus ostia in patients suffering from sinusitis. The system is based on flexible catheter and wire technology specifically designed to navigate the tortuous sinus anatomy with minimal trauma. All 510(k) products have been cleared by the U.S. Food and Drug Administration.

The Inspira AIR™ System
The Inspira AIR™ Balloon Dilation System is designed to safely dilate airway strictures with minimal mucosal trauma. Developed in partnership with otolaryngologists, the Inspira AIR™ Balloon Dilation System offers an elegant, minimally invasive solution for airway management. All 510(k) products have been cleared by the U.S. Food and Drug Administration.”

Johnson & Johnson said Wednesday it plans to acquire privately held medical-technology company Acclarent Inc. for $785 million in a deal that will boost J&J's presence in the ear, nose and throat treatment business.

J&J said the all-cash deal, which is expected to close in the first quarter, will lower the company's adjusted 2010 earnings by about three cents to four cents a share. The dilution is connected to the amortization of intangibles, including costs associated with in-process research and development and deal and integration costs, according to the company.

Analysts surveyed by Thomson Reuters expect, on average, J&J to post earnings of $4.93 a share next year. The health-care conglomerate is also expected to post 2010 sales of $63.91 billion.

Johnson & Johnson to Buy Acclarent for $785 Million - WSJ.com